SOAT1 and rheumatoid arthritis: It is interesting to note that tofacitinib, a potent inhibitor of the JAK family that has significantly improved the HI 3D phenotype, is already licensed for treating active psoriatic arthritis and rheumatoid arthritis (33), revealing the pertinence of targeting the JAK/STAT pathway in inflammatory skin diseases, such as HI.